Idarucizumab is a human monoclonal antibody that has a very high affinity to Dabigatran.

Life-threatening or uncontrolled bleeding.The reversal of anticoagulant effects is needed in the following conditions: Your physician might administer you a second dose of Praxbind 2.5gm Injection if bleeding reoccurs. The most frequently occurring side effect associated with anticoagulant use is bleeding, ranging from mild to severe complications. Your physician will prescribe this medicine when there is an emergency need to inactivate the anticoagulant effect of Dabigatran. It is indicated to reverse the anticoagulant effect of medicine called Dabigatran. Trial Registration: Not applicable.Īndexanet alfa anticoagulation cost healthcare resource utilization idarucizumab reversal.Praxbind 2.5gm Injection consists of the active substance Idarucizumab.

However, a higher prevalence of ICH bleeds was noted in the andexanet alfa group. Conclusions: Anticoagulant reversal therapy with idarucizumab was associated with significantly lower adjusted mean total hospital and ICU costs compared with andexanet alfa. Results: Idarucizumab patients were older than andexanet alfa patients (median age 81 vs 77 years p < 0.001), and less likely to experience intracranial hemorrhage (ICH) (37.1%vs 73.8% p = 0.001). Inverse of treatment probability weighting (IPTW) method was used to balance patient and clinical characteristics between treatment cohorts. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included patients aged ≥18 years on direct oral anticoagulants (DOACs) who experienced life-threatening bleeds, discharged from the hospital during -, and received idarucizumab or andexanet alfa. Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.

Idarucizumab price